Feed UCB.BR
UC

UCB

UCB.BR · BRU

209.30 € -0.57% (-1.20 €)
1M -2.55%
Market Cap 39.9B €
P/E Ratio 25.58x
Div. Yield 0.69%
ROE 14.76%

Bulios Fair Price

204.55 €

2.3% downside

Current Price

209.3 €

Undervalued Fair Value Overvalued

According to Bulios Fair Price, UCB.BR is currently trading close to its fair value. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
6/9
Valuation
50 /100
Fair
P/E 25.58x
EV/EBITDA 19.83x
P/S 5.15x
Growth
87 /100
Growing
EPS growth 56.24%
Rev. growth 11.95%
FCF growth 40.82%
Profitability
100 /100
Strong
Gross margin 74.29%
Net margin 20.13%
Op. margin 25.95%
Quality
65 /100
Average
ROIC 12.43%
ROE 14.76%
ROA 8.58%
Debt
95 /100
Low
Debt/Equity 0.21x
Current ratio 1.38x
Int. coverage 15.94x
Stability
36 /100
Moderate
Beta 0.20x
Rev. volatility 15.79%
EPS volatility 117.21%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about UCB.BR
Online

About the company

UCB SA (UCB) is a biopharmaceutical company based in Belgium, focusing on research, development, and production of medicinal products for the treatment of neurological and immunological disorders. The company specializes in medications for conditions such as epilepsy, Parkinson's disease, multiple sclerosis, and rheumatoid arthritis, among others. Their portfolio includes innovative drugs, biologic products, and prescription medications that improve the quality of life for patients suffering from these conditions. UCB also invests in research and development of new medications to provide effective and safe therapeutic options for patients worldwide. UCB SA (UCB) shares may be attractive to investors seeking investments in biopharmaceutical companies with an emphasis on innovation and treatment of neurological and immunological disorders.

Sector

Healthcare

Industry

Biotechnology

CEO

Jean-Christophe Tellier

Employees

9,000

Headquarters

Brussels

Upcoming events

25 FEB

Earnings

Upcoming earnings report

162d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.